Biofidelity developed a revolutionary molecular diagnostics.
Biofidelity developed a revolutionary molecular diagnostic assay that enables the rapid detection of target DNA sequences. Biofidelity’s mission is to improve and extend patients’ lives by enabling early detection of disease and better targeting of treatments with applications spanning oncology, prenatal testing, infectious disease, and organ transplant monitoring.Biofidelity was founded in 2019 and is headquartered of Cambridge, England.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 1, 2022 | Series A | $23M | 1 | Octopus Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Octopus Ventures | Yes | Series A |